Abstract:Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily affects elderly people and constitutes a major source of disability worldwide. Notably, the neuropathological hallmarks of PD include nigrostriatal loss and the formation of intracellular inclusion bodies containing misfolded α-synuclein protein aggregates. Cardinal motor symptoms, which include tremor, rigidity and bradykinesia, can effectively be managed with dopaminergic therapy for years following symptom onset. Nonetheless, patients ultimately develop symptoms that no longer fully respond to dopaminergic treatment. Attempts to discover disease-modifying agents have increasingly been supported by translational molecular imaging concepts, targeting the most prominent pathological hallmark of PD, α-synuclein accumulation, as well as other molecular pathways that contribute to the pathophysiology of PD. Indeed, molecular imaging modalities such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT) can be leveraged to study parkinsonism not only in animal models but also in living patients. For instance, mitochondrial dysfunction can be assessed with probes that target the mitochondrial complex I (MC-I), while nigrostriatal degeneration is typically evaluated with probes designed to non-invasively quantify dopaminergic nerve loss. In addition to dopaminergic imaging, serotonin transporter and N-methyl-D-aspartate (NMDA) receptor probes are increasingly used as research tools to better understand the complexity of neurotransmitter dysregulation in PD. Non-invasive quantification of neuroinflammatory processes is mainly conducted by targeting the translocator protein 18 kDa (TSPO) on activated microglia using established imaging agents. Despite the overwhelming involvement of the brain and brainstem, the pathophysiology of PD is not restricted to the central nervous system (CNS). In fact, PD also affects various peripheral organs such as the heart and gastrointestinal tract - primarily via autonomic dysfunction. As such, research into peripheral biomarkers has taken advantage of cardiac autonomic denervation in PD, allowing the differential diagnosis between PD and multiple system atrophy with probes that visualize sympathetic nerve terminals in the myocardium. Further, α-synuclein has recently gained attention as a potential peripheral biomarker in PD. This review discusses breakthrough discoveries that have led to the contemporary molecular concepts of PD pathophysiology and how they can be harnessed to develop effective imaging probes and therapeutic agents. Further, we will shed light on potential future trends, thereby focusing on potential novel diagnostic tracers and disease-modifying therapeutic interventions.

Patient-centered Transcriptomic and Multimodal Neuroimaging Determinants of Clinical Progression, Physical Activity and Treatment Needs in Parkinson Disease

Identification of Parkinson’s Disease PACE Subtypes and Repurposing Treatments Through Integrative Analyses of Multimodal Data

Genome-wide Survival Study Identifies a Novel Synaptic Locus and Polygenic Score for Cognitive Progression in Parkinson’s Disease

Translational molecular imaging and drug development in Parkinson's disease

Unraveling the Complexity of Parkinson's Disease: Insights into Pathogenesis and Precision Interventions

Druggable transcriptomic pathways revealed in Parkinson's patient-derived midbrain neurons

Emerging perspectives on precision therapy for Parkinson's disease: multidimensional evidence leading to a new breakthrough in personalized medicine

Two Distinct Trajectories of Clinical and Neurodegeneration Events in Parkinson’s Disease

Elucidating Molecular Networks Underpinning Heterogeneity in Parkinson’s Disease Progression Across Clinical Manifestation Spectrum

Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes

Patient-specific models link neurotransmitter receptor mechanisms with motor and visuospatial axes of Parkinson’s disease

From Diagnosis to Treatment: A Comprehensive Review of Biomarkers and Therapeutic Advances in Parkinson’s Disease

Parkinson’s Disease: From Pathogenesis to Pharmacogenomics

Genome-wide Analysis of Motor Progression in Parkinson Disease

Personalized Progression Modelling and Prediction in Parkinson’s Disease with a Novel Multi-Modal Graph Approach

Imaging biomarkers in Parkinson’s disease and Parkinsonian syndromes: current and emerging concepts

Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials

Proteogenomic network analysis reveals dysregulated mechanisms and potential mediators in Parkinson's disease

Toward Precision Medicine in Parkinson's Disease.

Nuclear and Mitochondrial Genome, Epigenome and Gut Microbiome: Emerging Molecular Biomarkers for Parkinson's Disease